Nature medicine · 2023
Cerebellar deep brain stimulation for chronic post-stroke motor rehabilitation: a phase I trial.
Клиническое исследование I фазыСтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baker Kenneth B, Plow Ela B, Nagel Sean, Rosenfeldt Anson B, Gopalakrishnan Raghavan, Clark Cynthia, Wyant Alexandria, Schroedel Madeleine, Ozinga John, Davidson Sara, Hogue Olivia, Floden Darlene, Chen Jacqueline, Ford Paul J, Sankary Lauren, Huang Xuemei, Cunningham David A, DiFilippo Frank P, Hu Bo, Jones Stephen E, Bethoux Francois, Wolf Steven L, Chae John, Machado André G
Аннотация
Upper-extremity impairment after stroke remains a major therapeutic challenge and a target of neuromodulation treatment efforts. In this open-label, non-randomized phase I trial, we applied deep brain stimulation to the cerebellar dentate nucleus combined with renewed physical rehabilitation to promote functional reorganization of ipsilesional cortex in 12 individuals with persistent (1-3 years), moderate-to-severe upper-extremity impairment. No serious perioperative or stimulation-related adverse events were encountered, with participants demonstrating a seven-point median improvement on the Upper-Extremity Fugl-Meyer Assessment. All individuals who enrolled with partial preservation of distal motor function exceeded minimal clinically important difference regardless of time since stroke, with a median improvement of 15 Upper-Extremity Fugl-Meyer Assessment points. These robust functional gains were directly correlated with cortical reorganization evidenced by increased ipsilesional metabolism. Our findings support the safety and feasibility of deep brain stimulation to the cerebellar dentate nucleus as a promising tool for modulation of late-stage neuroplasticity for functional recovery and the need for larger clinical trials. ClinicalTrials.gov registration: NCT02835443 .